title: Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.
abstract: BACKGROUND
  Specific immunotherapy (SIT) duration for respiratory allergy is currently based on individual decisions.
  
  
  OBJECTIVE
  To evaluate the differences in clinical efficacy of SIT as a result of the duration between the current recommended limits (3-5 years).
  
  
  METHODS
  A 5-year prospective, controlled clinical trial of SIT blind until the first year and randomization to a 3-year (IT3) or 5-year (IT5) course was conducted. Of the 239 patients with respiratory allergy caused by D pteronyssinus initially included, 142 completed 3 years of SIT with good compliance. Twenty-seven controls were included at the third year. Efficacy of SIT after 3 (T3) and 5 (T5) years was assessed by using clinical scores, visual analog scales (VASs), rhinitis (RQLQ) and asthma (AQLQ) quality of life questionnaires, skin tests, and serum immunoglobulins.
  
  
  RESULTS
  At T3, significant reductions were observed in rhinitis (44% in IT3 and 50% in IT5; P < .001), asthma (80.9 % in IT3 and 70.9% in IT5; P < .001) scores, VAS (P < .001 in both), RQLQ (P < .001 in both) and AQLQ (P < .001 in both). At T5, the clinical benefit was maintained in both groups, and IT5 patients presented additional decreases (19%; P = .019) in rhinitis scores. At Tf, specific IgG(4) measurements were lower in IT3 (P = .03) without detecting differences in IT5. An increase in asthma score of 133% was the only difference observed in controls.
  
  
  CONCLUSIONS
  Clinical improvement is obtained with 3 years of D pteronyssinus SIT. Two additional years of SIT add clinical benefit in rhinitis only.
authors.affiliation: Department of Allergy, Hospital Virgen del Camino, Pamplona, Spain. ana.tabar.purroy@cfnavarra.es
authors.forename: Ana I
authors.initials: AI
authors.lastname: Tabar
authors.forename: Esozia
authors.initials: E
authors.lastname: Arroabarren
authors.forename: Susana
authors.initials: S
authors.lastname: Echechipía
authors.forename: Blanca E
authors.initials: BE
authors.lastname: García
authors.forename: Santiago
authors.initials: S
authors.lastname: Martin
authors.forename: María J
authors.initials: MJ
authors.lastname: Alvarez-Puebla
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000008:administration & dosage* / Q000276:immunology; D060829:Arthropod Proteins; D002648:Child; D003546:Cysteine Endopeptidases; D003888:Desensitization, Immunologic / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D039981:Pyroglyphidae / Q000276:immunology*; D011788:Quality of Life; D012130:Respiratory Hypersensitivity / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D039741:Antigens, Dermatophagoides; D060829:Arthropod Proteins; C451163:Dermatophagoides pteronyssinus antigen p 2; D003546:Cysteine Endopeptidases; C451162:Dermatophagoides pteronyssinus antigen p 1